
A round up of some of the key themes in pharma’s yearEUROPE IN CRISIS While the Eurozone has averted meltdown …

Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
2011 should be a better year for pharma as emerging markets and recovering economies will help growth, say analysts at …

